MedPath

Trial for Treating Painful Degenerative Disc Disease

Not Applicable
Recruiting
Conditions
Degenerative Disc Disease
Interventions
Biological: Platelet-rich plasma (PRP), Platelet lysate (PL), and Platelet Poor Plasma (PPP)
Other: Sham procedure
Registration Number
NCT05287867
Lead Sponsor
Regenexx, LLC
Brief Summary

To evaluate and compare two platelet-based treatments of the functional spinal unit spaced 4 weeks apart to sham procedures for the treatment of degenerative disc disease.

Detailed Description

This is a single-blind, randomized, placebo-controlled study using platelet-based treatment to the functional spinal unit .in a series of 2 treatments 4 weeks apart to treat painful lumbar degenerative disc disease. Randomization is 2:1, with 28 in the treatment group and 14 in the sham control group.

A pretreatment visit will occur at or before the time of enrollment; follow-up visits will occur at the clinical site at 3- and 12 months post injection. Target enrollment is 42 subjects. Patients in the control group can crossover to the treatment group after 3-month follow-up. Crossover patients then follow the treatment group follow-up timeline based on their second real treatment. Subjects will complete the study following the 1-year follow-up visit.

The primary objective of this study is to observe the improvement in subject-reported clinical outcomes from baseline to 3 months after 2nd treatment and between groups at 3 months, with continued evaluation of efficacy and durability up to 12 months. Questionnaires are completed at 1, 3, 6, and 12 months.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
42
Inclusion Criteria
  • Voluntary signature of the IRB approved Informed Consent,
  • Skeletally mature Male or Female ages 25 to 65
  • Maximum of 3 levels degenerative disc disease without significant spondylolisthesis in the area c/w the pain (grade 1 with less than or equal to 10% vertebral body)
  • Chronic back and/or leg pain having failed conservative treatment (e.g. NSAIDs, physician initiated physical therapy) for at least 6 months
  • MRI and physical examination consistent with painful Degenerative Disc Disease
  • Failure of epidural steroid injection, facet injection, medial branch block, radiofrequency ablation or physical therapy
  • Instability as seen on MRI, flexion-extension x-ray, or physical deformity as seen on MRI c/w degenerative instability (facet hypertrophy, loss of disc height, spondylolisthesis, laterolisthesis, osteophytes)
  • A lumbar surgery candidate (will need to specify which surgery, ie. fusion, decompression, etc)
  • Is independent, ambulatory, and can comply with all post-operative evaluations and visits

Exclusion criteria:

  • Evidence of more than moderate central canal or foraminal stenosis
  • Smoker or cessation for less than 6 weeks
  • Untreated underlying psychological conditions (e.g. depression, chronic pain syndrome, etc.) as a contributor to chronic pain
  • Prior epidural steroid injection within the past 8 weeks
  • Degenerative scoliosis if cob angle over 10 degrees
  • Undergone previous Regenexx lumbar procedure
  • Standing intolerance (patient cannot stand longer than 30 minutes)
  • Inflammatory or auto-immune based pathology (e.g., rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, polymyalgia, polymyositis, gout pseudogout)
  • Severe neurogenic inflammation of the cutaneous nerves
  • Condition represents a worker's compensation case
  • Currently involved in a health-related litigation procedure
  • Is pregnant
  • Bleeding disorders
  • Currently taking anticoagulant or immunosuppressive medication
  • Allergy or intolerance to study medication
  • Use of chronic opioid
  • Documented history of drug abuse within six months of treatment
  • Central sensitization
  • Hypermobile or EDS
    1. Any other condition, that in the opinion of the investigator, that would preclude the patient from enrollment
Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Platelet treatmentPlatelet-rich plasma (PRP), Platelet lysate (PL), and Platelet Poor Plasma (PPP)A series of two treatments spaced 4 weeks apart that include platelet-rich plasma (PRP). platelet lysate (PL), and platelet poor plasma (PPP).
Sham procedureSham procedureA series of two sham procedures spaced 4 weeks apart.
Primary Outcome Measures
NameTimeMethod
Numeric Pain Scale (NPS)3-months after 2nd treatment

Difference in Numeric Pain Scale group differences (scale 0-10, where 0=no pain and 10=worst possible pain

Modified Single Assessment Numerical Evaluation (SANE) scores3-months after 2nd treatment

Difference in modified Single Assessment Numerical Evaluation score group differences; scores range from 0-100 where 0=no improvement and 100=100% improved

Secondary Outcome Measures
NameTimeMethod
Numeric Pain Scale (NPS)Baseline, 1-month, 3-months, 6 months, 12 months

Changes in NPS from pre to post treatment; scale ranges from 0-10 where 0=no pain and 10=worst possible pain

Functional Rating Index (FRI)Baseline, 1-month, 3-months, 6 months, 12 months

Changes in FRI from pre to post treatment and between group differences at 1 and 3 months; scales 0-100% where 0%=no disability and 100%=very severe disability

Incidence rate of adverse events1 month, 3 months, 6 months and 12 months

Incidence of adverse events after treatment

Mean modified SANE scores1-month, 3-months, 6 months, 12 months

Average SANE scores post-treatment; scores range from 0-100 where 0=no improvement and 100=100% improved

Oswestry Disability Index (ODI)Baseline, 1-month, 3-months, 6 months, 12 months

Changes in ODI from pre to post and between group differences at 1 and 3 months; scales 0-100% where 0%=no disability and 100%=very disabled.

Incidence rate of surgical/other treatment interventions1 month, 3 months , 6 months and 12 months

Incidence of surgical/other treatment interventions after treatment

Pain medications1 month, 3 months, 6 months and 12 months

Changes in medications from pre to post treatment

Trial Locations

Locations (1)

Centeno-Schultz Clinic

🇺🇸

Lone Tree, Colorado, United States

© Copyright 2025. All Rights Reserved by MedPath